Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691366 · ClinicalTrials.gov registry record
Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis
A clinical trial, sponsored by Wake Forest University.
- Completed
- Registry status
- 45
- Enrollment target
NCT00691366: Completed study, sponsored by Wake Forest University.
NCT00691366 is a clinical trial that has completed, run by Wake Forest University. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00691366 has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
The purpose of this research is to study heart rate patterns in people with moderate to severe atopic dermatitis and how itching affects those patterns.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-12 |
What the finished NCT00691366 record still lists
NCT00691366 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00691366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00691366 about?
NCT00691366 is a clinical study titled "Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis". The purpose of this research is to study heart rate patterns in people with moderate to severe atopic dermatitis and how itching affects those patterns.
What is the current status of trial NCT00691366?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2007-03. Estimated completion is 2009-12.
Who is sponsoring clinical trial NCT00691366?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia